Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Klinische Wirksamkeit (39 Abbildungen)
Übersicht


Abb. 0: FÜR ÖSTERREICH: Weitere Informationen: Merck Gesellschaft mbH, Zimbagasse 5, 1147 Wien, Tel.: 01/576 00-0 Abb. 1: Micardis(R) - Klinische Wirksamkeit Abb. 2: Micardis - Vergleichsstudien Aktuelles Bild - Abb. 3: Datenbestand - Langzeitmessung Abb. 4: Blutdrucksenkung - 24 Stunden Abb. 5: Morgendliche Blutdrucksenkung Abb. 6: Morgendliche Blutdrucksenkung - Angiotensin-I-Rezeptorblocker Zum letzten Bild
Abbildung 3: Datenbestand - Langzeitmessung
Clinical trials of telmisartan have extensively used ABPM, which is widely considered to be the most relevant measure of blood pressure. This extensive use of ABPM has resulted in the largest body of ABPM data currently available. This slide provides a list of studies that have been conducted to date, and which are detailed in the following slides. Additional ABPM studies are ongoing, which will increase further the body of available data.
 
Datenbestand - Langzeitmessung
Vorheriges Bild Nächstes Bild   


Abbildung 3: Datenbestand - Langzeitmessung
Clinical trials of telmisartan have extensively used ABPM, which is widely considered to be the most relevant measure of blood pressure. This extensive use of ABPM has resulted in the largest body of ABPM data currently available. This slide provides a list of studies that have been conducted to date, and which are detailed in the following slides. Additional ABPM studies are ongoing, which will increase further the body of available data.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung